

**A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers**

Dominik Glodzik, Sandro Morganella, Helen Davies, Peter T Simpson, Yilong Li, Xueqing Zou, Javier Diez-Perez, Johan Staaf, Ludmil B Alexandrov, Marcel Smid, et al.

► **To cite this version:**

Dominik Glodzik, Sandro Morganella, Helen Davies, Peter T Simpson, Yilong Li, et al. A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. *Nature Genetics*, Nature Publishing Group, 2017, 49 (3), pp.341 - 348. <10.1038/ng.3771>. <hal-01525728v2>

**HAL Id: hal-01525728**

**<https://hal.inria.fr/hal-01525728v2>**

Submitted on 30 Jun 2017

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# **A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers**

## **Authors**

Dominik Glodzik<sup>1</sup>, Sandro Morganella<sup>1</sup>, Helen Davies<sup>1</sup>, Peter T. Simpson<sup>2</sup>, Yilong Li<sup>1</sup>, Xueqing Zou<sup>1</sup>, Javier Diez-Perez<sup>1</sup>, Johan Staaf<sup>3</sup>, Ludmil B. Alexandrov<sup>1,4,5</sup>, Marcel Smid<sup>6</sup>, Arie B Brinkman<sup>7</sup>, Inga Hansine Rye<sup>8,9</sup>, Hege Russnes<sup>8,9</sup>, Keiran Raine<sup>1</sup>, Colin A. Purdie<sup>10</sup>, Sunil R Lakhani<sup>2,11</sup>, Alastair M. Thompson<sup>10,12</sup>, Ewan Birney<sup>13</sup>, Hendrik G Stunnenberg<sup>6</sup>, Marc J van de Vijver<sup>14</sup>, John W.M. Martens<sup>6</sup>, Anne-Lise Børresen-Dale<sup>8,9</sup>, Andrea L. Richardson<sup>15,16</sup>, Gu Kong<sup>17</sup>, Alain Viari<sup>18,19</sup>, Douglas Easton<sup>20</sup>, Gerard Evan<sup>21</sup>, Peter J Campbell<sup>1</sup>, Michael R. Stratton<sup>1</sup> and Serena Nik-Zainal<sup>1,22</sup>

## **Affiliations**

1 Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom

2 University of Queensland: Centre for Clinical Research and School of Medicine, Brisbane, Australia

3 Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

4 Theoretical Biology and Biophysics (T-6), Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America

5 Center for Nonlinear Studies, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America

6 Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, The Netherlands

7 Radboud University, Department of Molecular Biology, Faculties of Science and Medicine, Nijmegen, Netherlands

8 Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital The Norwegian Radiumhospital

9 K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway

10 Department of Pathology, Ninewells Hospital & Medical School, Dundee DD1 9SY, UK

11 Pathology Queensland, The Royal Brisbane and Women's Hospital, Brisbane, Australia

12 Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, Texas 77030

13 European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SD

14 Department of Pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands

15 Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115 USA

16 Dana-Farber Cancer Institute, Boston, MA 02215 USA

17 Department of Pathology, College of Medicine, Hanyang University, Seoul, South Korea

18 Equipe Erable, INRIA Grenoble-Rhône-Alpes, 655, Av. de l'Europe, 38330 Montbonnot-Saint Martin, France

19 Synergie Lyon Cancer, Centre Léon Bérard, 28 rue Laënnec, Lyon Cedex 08, France

20 Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, United Kingdom.

21 Department of Biochemistry, University of Cambridge CB2 1GA, United Kingdom.

22 East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 9NB, UK

**Corresponding authors:**

Serena Nik-Zainal ([snz@sanger.ac.uk](mailto:snz@sanger.ac.uk))

**Summary**

Somatic rearrangements contribute to the mutagenized landscape of human cancer genomes. Here, we systematically interrogated catalogues of somatic rearrangements of 560 breast cancers<sup>1</sup> to identify hotspots of recurrent rearrangements, specifically tandem duplications, because of previous anecdotal reports of tandem duplications that recurred in different patients. We highlight 33 rearrangement hotspots associated with a signature of Homologous Recombinational (HR) repair deficiency, characterized mainly by large (>100kb) tandem duplications. These hotspots are enriched for breast cancer germline susceptibility loci and breast-specific “super-enhancer” regulatory elements, and have a propensity for wholly duplicating these genomic features as well as well-known breast cancer oncogenes. They could represent sites of selective susceptibility to rearrangement mutagenesis and through incrementally increasing copy number, represent sites of secondary selective pressure. Corroborative transcriptomic evidence was observed ranging from strong individual oncogene effects through to weak but quantifiable global gene expression effects. Furthermore, in an independent cohort of WGS ovarian cancers, seven long tandem duplication hotspots were detected that intriguingly demonstrated enrichment for ovarian-specific super enhancers. We thus present these tandem duplication hotspots as evidence of a rearrangement signature that exerts its influence through the coding sequence and through non-coding regulatory elements, contributing a continuum of consequences ranging from inconsequential through to strong oncogenic effects, making this rearrangement mutational process particularly deleterious.

## **Introduction**

Whole genome sequencing (WGS) has permitted unrestricted access to the human cancer genome, triggering the hunt for driver mutations that could confer selective advantage in all parts of human DNA. Recurrent somatic mutations in coding

sequences are often interpreted as driver mutations particularly when supported by transcriptomic changes or functional evidence. However, recurrent somatic mutations in non-coding sequences are less straightforward to interpret. Although *TERT* promoter mutations in malignant melanoma<sup>2,3</sup> and *NOTCH1* 3' region mutations in chronic lymphocytic leukaemia<sup>4</sup> have been successfully demonstrated as driver mutations, multiple non-coding loci have been highlighted as recurrently mutated but evidence supporting these as true drivers remains lacking. Indeed, in a recent exploration of 560 breast cancer whole genomes<sup>1</sup>, the largest cohort of WGS cancers to date, statistically significant recurrently mutated non-coding sites (by substitutions and insertions/deletions (indels)) were identified but alternative explanations for localized elevation in mutability such as a propensity to form secondary DNA structures were observed<sup>1</sup>.

These efforts have been focused on recurrent substitutions and indels and an exercise seeking sites that are recurrently mutated through rearrangements has not been formally performed. Such sites could be indicative of driver loci under selective pressure (such as amplifications of *ERBB2* and *CCND1*) or could represent highly mutable sites that are simply prone to double-strand break (DSB) damage. Sites that are under selective pressure generally have a high incidence in a particular tissue-type, are highly complex and comprise multiple classes of rearrangement including deletions, inversions, tandem duplications and translocations. By contrast, sites that are simply breakable may show a low frequency of occurrence and demonstrate a preponderance of a particular class of rearrangement, a harbinger of susceptibility to a specific mutational process.

An anecdotal observation in the cohort of 560 breast cancers was of sites in the genome that appeared to be rearranged recurrently, albeit at a low frequency, and by a very specific rearrangement class of tandem duplications. Rarely, tandem duplications recurred at approximately the same locus in the same cancer resulting in the appearance of nested tandem duplications. No explanation was provided for this observation. Here, we have taken a novel approach to systematically seek sites in the human cancer genome that are recurrently mutagenized by rearrangements, specifically tandem duplications, in order to fully understand the prevalence and the impact of these sites of recurrent tandem duplications in this cohort of breast cancers.

In all, 77,695 rearrangements including 59,900 intra-chromosomal (17,564 deletions, 18,463 inversions and 23,873 tandem duplications) and 17,795 inter-chromosomal translocations were identified in this cohort previously. The distribution of rearrangements within each cancer was complex (Figure 1A-D); some had few rearrangements without distinctive patterns, some had collections of focally occurring rearrangements such as amplifications, whereas many had rearrangements distributed throughout the genome - indicative of very different set of underpinning mutational processes.

Thus, large, focal collections of “clustered” rearrangements were first separated from rearrangements that were widely distributed or “dispersed” in each cancer, then distinguished by class (inversion, deletion, tandem duplication or translocation) and size (1-10kb, 10-100kb, 100kb-1Mb, 1-10Mb, more than 10Mb)<sup>1</sup>, before a mathematical method for extracting mutational signatures was applied<sup>5</sup>. Six rearrangement signatures were extracted (RS1-RS6) representing discrete rearrangement mutational processes in breast cancer<sup>1</sup>. Two distinctive mutational processes in particular were associated with dispersed tandem duplications. RS1 and RS3 are mostly characterized by large (>100kb) and small (< 10kb) tandem duplications, respectively (Figure 1E). Although both are associated with tumors that are deficient in homologous recombination (HR) repair<sup>6-9</sup>, RS3 is specifically associated with inactivation of *BRCA1*. Thus, because they represent distinct biological defects in human cells, we have chosen to proceed with a systematic analysis of sites of recurrent mutagenesis of these two mutational signatures as independent processes.

We identified a surprising number of rearrangement hotspots dominated by the RS1 mutational process characterised by long (>100kb) tandem duplications<sup>1</sup>. Intuitively, a hotspot of mutagenesis that is enriched for a particular mutational signature implies a propensity to DNA double-strand break (DSB) damage and specific recombination-based repair mutational mechanisms that could explain these tandem duplication hotspots. However, we find additional intriguing features associated with these hotspots that challenge current perceptions in cancer biology, explained below.

## Results

### *Identification of rearrangement hotspots*

In order to systematically identify hotspots of tandem duplications through the genome, we first considered the background distribution of rearrangements that is known to be non-uniform. A regression analysis was performed to detect and quantify the associations between the distribution of rearrangements and a variety of genomic landmarks including replication time domains, gene-rich regions, background copy number, chromatin state and repetitive sequences (Supplementary materials and Supplementary Figure S1). The associations learned were taken into consideration creating an adjusted background model and were also applied during simulations, these steps being critical to the following phase of hotspot detection. Adjusted background models and simulated distributions were calculated for RS1 and RS3 tandem duplication signatures separately because of vastly differing numbers of rearrangements in each signature of 5,944 and 13,498 respectively, which could bias the detection of hotspots for the different signatures.

We next employed the principle of intermutation distance<sup>10</sup> (IMD)- the distance from one breakpoint to the one immediately preceding it in the reference genome and used a piece-wise constant fitting (PCF) approach<sup>11,12</sup>, a method of segmentation of sequential data that is frequently utilised in analyses of copy number data. PCF was applied to the IMD of RS1 and RS3 separately, seeking segments of the breast cancer genomes where groups of rearrangements exhibited short IMD, indicative of “hotspots” that are more frequently rearranged than the adjusted background model (Figure 2, Supplementary Materials). The parameters used for the PCF algorithm were optimised against simulated data (Supplementary Materials and Supplementary Figure S2). We aimed to detect a conservative number of hotspots while minimising the number of false positive hotspots. Note that all highly clustered rearrangements such as those causing driver amplicons had been previously identified in each sample and removed, and thus do not contribute to these hotspots. However, to ensure that a hotspot did not comprise only a few samples with multiple breakpoints each, a minimum of eight samples was required to contribute to each hotspot. Of note, this

method negates the use of genomic bins and permits detection of hotspots of varying genomic size.

Thus, the PCF method was applied to RS1 and RS3 rearrangements separately, seeking loci that have a rearrangement density exceeding twice the local adjusted background density for each signature and involving a minimum of eight samples. Interestingly, 0.5% of 13,498 short RS3 tandem duplications contributed towards four RS3 hotspots. By contrast, 10% of 5,944 long RS1 tandem duplications formed 33 hotspots demonstrating that long RS1 tandem duplications are 20 times more likely to form a rearrangement hotspot than short RS3 tandem duplications. Indeed, these were visible as punctuated collections of rearrangements in genome-wide plots of rearrangement breakpoints (Figure 2C and Supplementary Table S1).

### ***Contrasting RS3 hotspots to RS1 hotspots***

RS3 hotspots had different characteristics to that of RS1 hotspots. The four RS3 hotspots were highly focused, occurred in small genomic windows and exhibited very high rearrangement densities (range 61.8 to 658.3 breakpoints per Mb (Figure 3B). In contrast, the 33 RS1 hotspots had densities between 7.6 and 83.2 breakpoints per Mb and demonstrated other striking characteristics (Figure 3A). In several RS1 hotspots, duplicated segments showed genomic overlap between patients, even when most patients had only one tandem duplication, as depicted in a cumulative plot of duplicated segments for samples contributing rearrangements to a hotspot (Figure 3C, Supplementary Figure S3). Interestingly, the nested tandem duplications that were observed incidentally in the past, were a particular characteristic of RS1 hotspots. The hotspots of RS1 and RS3 were distinct from one another apart from one locus where two lncRNAs *NEAT1* and *MALAT1* reside (discussed in Section 7 of Supplementary Materials).

Assessing the potential genomic consequences of RS1 and RS3 tandem duplications on functional components of the genome, RS1 rearrangements were observed to duplicate important driver genes and regulatory elements while RS3 rearrangements were found to mainly transect them (Supplementary materials section 8 and Figure 4). This is likely to be related to the size of tandem duplications in these signatures. Short



(<10kb) RS3 tandem duplications are more likely to duplicate very small regions, with the effect equivalent of disrupting genes or regulatory elements. In contrast, RS1 tandem duplications are long (>100kb), and would be more likely to duplicate whole genes or regulatory elements.

Strikingly, the effects were strongest for tandem duplications that contributed to hotspots of RS1 and RS3 than they were for tandem duplications that were not in hotspots or that were simulated. Thus, although the likelihood of transection/duplication may be governed by the size of tandem duplications, the particular enrichment for hotspots must carry important biological implications.

The enrichment of disruption of tumour suppressor genes by RS3 hotspots (OR 167,  $P=9.4 \times 10^{-41}$  by Fisher's exact test) and is relatively simple to understand - these are likely to be under selective pressure. Accordingly, two of the four RS3 hotspots occurred within well-known tumour suppressors, *PTEN* and *RBI*. Other rearrangement classes are also enriched in these genes in-keeping with being driver events (Section 7 of Supplementary Materials, Supplementary Table S2). Furthermore, these sites were identified as putative driver loci in an independent analysis seeking driver rearrangements through gene-based methods<sup>1</sup>.

By contrast, the enrichment of oncogene duplication by RS1 hotspots (OR 1.49,  $P=4.1 \times 10^{-3}$  by Fisher's exact test) was apparent<sup>13</sup>, although not as strong as the enrichment of transections of cancer genes by RS3 hotspots. More notably, the enrichment of other putative regulatory features was also observed. Indeed, we observed that susceptibility loci associated with breast cancer<sup>14,15</sup> were 4.28 times more frequent in an RS1 hotspot than in the rest of the tandem duplicated genome (Supplementary Figure S4A,  $P=3.4 \times 10^{-4}$  in Poisson test). Additionally, 18 of 33 (54.5%) RS1 tandem duplication hotspots contained at least one breast super-enhancer. The density of breast super-enhancers was 3.54 times higher in a hotspot compared to the rest of the tandem duplicated genome (Supplementary Figure S4B,  $P=7.0 \times 10^{-16}$  Poisson test). This effect was much stronger than for non-breast tissue super-enhancers (OR 1.62) or enhancers in general (OR 1.02, Supplementary Table S3). This gradient reinforces how the relationship between tandem duplication hotspots and regulatory elements deemed as super-enhancer, is tissue-specific.

The reason underlying these observations in RS1 hotspots however is a little less clear. Single or nested tandem duplications in RS1 hotspots effectively increase the number of copies of a genomic region but only incrementally. The enrichment of breast cancer specific susceptibility loci, super-enhancers and oncogenes at hotspots of a very particular mutational signature could reflect an increased likelihood of damage and thus susceptibility to a passenger mutational signature that occurs because of the high transcriptional activity associated with such regions. However, it is also intriguing to consider that the resulting copy number increase could confer some more modest selective advantage and contribute to the driver landscape. To investigate the latter possibility, we explored the impact of RS1 tandem duplications on gene expression.

### ***Impact of RS1 hotspots on expression***

Several RS1 hotspots involved validated breast cancer genes (e.g. *ESR1*, *ZNF217*, Supplementary Figure S6, S7) and could conceivably contribute to the driver landscape through increasing the number of copies of a gene - even if by only a single copy.

*ESR1* is an example of a breast cancer gene that is a target of an RS1 hotspot. In the vicinity of *ESR1* is a breast tissue specific super-enhancer and a breast cancer susceptibility locus. Fourteen samples contribute to this hotspot, of which ten have only a single tandem duplication or simple nested tandem duplications of this site. Six samples had expression data and all showed significantly elevated levels of *ESR1* despite modest copy number increase (Supplementary Figure S6a). Four samples have a small number of rearrangements (< 30) yet have a highly specific tandem duplication of *ESR1*, suggestive of selection. Most other samples with rearrangements in the other 32 hotspots were triple negative tumours. By contrast, samples with rearrangements in the *ESR1* hotspot showed a different preponderance – eleven of fourteen were estrogen receptor positive tumours. Thus we propose that the duplications in the *ESR1* hotspot are putative drivers that would not have been

detected using customary copy number approaches previously, but are likely to be important to identify because of the associated risk of developing resistance to anti-estrogen chemotherapeutics<sup>16,17</sup>.

*c-MYC* encodes a transcription factor that coordinates a diverse set of cellular programs and is deregulated in many different cancer types<sup>18,19</sup>. 30 patients contributed to the RS1 hotspot at the *c-MYC* locus with modest copy number gains. A spectrum of genomic outcomes was observed including single or nested tandem duplications, flanking (16 samples) or wholly duplicating the gene body of *c-MYC* (14 samples) (Figure 5A). Notably, a breast tissue super-enhancer and two germline susceptibility loci lie in the vicinity of *c-MYC*<sup>20 15</sup>(Figure 5B). We had a larger number of samples with corresponding RNA-seq data and thus modeled the expression levels of *c-MYC* taking breast cancer subtype, background copy number (whole chromosome arm gain is common for chr 8) and sought whether tandem duplicating a gene was associated with increased transcription. We find that tandem duplications in the RS1 hotspot were associated with a doubling of the expression level of *c-MYC* (0.99 s.e. 0.28 log<sub>2</sub> FPKM, P=4.4 × 10<sup>-4</sup> in t-test) (Supplementary Table S4).

The expression-related consequences of tandem duplications of putative regulatory elements however, is more difficult to assess because of the uncertainty of the downstream targets of these regulatory elements. We have thus taken a global gene expression approach and applied a mixed effects model to understand the contribution of tandem duplications of these elements, controlling for breast cancer subtype and background copy number. We find that tandem duplications involving a super-enhancer or breast cancer susceptibility locus are associated with an increase in levels of global gene expression even when the gene itself is not duplicated. The effect is strongest on oncogenes (0.30 +- 0.20 log<sub>2</sub> FPKM, P=0.12 in ANOVA test) than for other genes (0.16 s.e. 0.04 log<sub>2</sub> FPKM, P=1.8 × 10<sup>-4</sup> in ANOVA test) within RS1 hotspots or for genes in the rest of the genome (Supplementary Table S4).

Thus, tandem duplications of cancer genes demonstrate strong expression effects in individual genes (e.g. *ESR1* and *c-MYC*) while tandem duplications of putative regulatory elements demonstrate modest but quantifiable global gene expression

effects. The spectrum of functional consequences at these loci could thus range from insignificance, through mild enhancement, to strong selective advantage – consequences of the same somatic rearrangement mutational process.

### ***Long tandem duplication hotspots are present and distinct in other cancers***

We additionally explored other cancer cohorts where sequence files were available. Two cancer types are known to exhibit tandem duplications, particularly pancreatic and ovarian cancers. Raw sequence files were parsed through our mutation-calling algorithms and rearrangement signatures extracted as for breast cancers. Adjusted background models and simulations were performed on these new datasets separately. The total number of available samples was much smaller than the breast cancer cohort, which is currently the largest cohort of WGS cancers of a single cancer type in the world. Thus power for detecting hotspots was substantially reduced particularly for pancreatic cancer. Nevertheless, in ovarian tumours 2,923 RS1 rearrangements were found and seven RS1 hotspots identified, of which six were distinct from breast cancer RS1 hotspots. A marked enrichment for ovarian cancer specific super-enhancers (11 super-enhancers over 20.2 Mb, OR 2.9,  $P=1.9 \times 10^{-3}$  in Poisson test) was also noted for these hotspots. *MUC1*, a validated oncogene in ovarian cancer was the focus at one of the hotspots. Thus, although we require larger cohorts of WGS cancers in the future to be definitive, the presentiment is that different cancer-types could have different RS1 hotspots that are focused at highly transcribed sites specific to different tissues.

### ***Discussion: Selective susceptibility or selective pressure?***

Rearrangement signatures may, in principle, be mere passenger read-outs of the stochastic mayhem in cancer cells. However, mutational signatures recurring at specific genomic sites, which also coincide with distinct genomic features, suggest a more directed nature – a sign of either selective susceptibility or selective pressure.

Perhaps it is an attribute of being more highly active or transcribed (e.g. super-enhancers) or some other as yet unknown quality (e.g. germline SNP sites and other

hotspots with no discerning features), these hotspots exemplify loci that are rendered more available for DSB damage and more dependent on repair that generates large tandem duplications<sup>6,21-23</sup>. They signify genomic sites that are innately more susceptible to the HR-deficient tandem duplication mutational process – sites of selective susceptibility.

An alternative argument could also hold true: It could be that the likelihood of damage/repair relating to this mutational process is similar throughout the genome. However, through incrementally increasing the number of copies of coding genes that drive tissue proliferation, survival and invasion (*ESR1*, *ZNF217*) or non-coding regions that have minor or intermediate modifying effects in cancer such as germline susceptibility loci or super-enhancer elements, long tandem duplications (unlike other classes of rearrangements) could specifically enhance the overall likelihood of carcinogenesis. The profound implication is that these loci do come under a degree of selective pressure, and that this HR-deficient tandem duplication mutational process is in fact a novel mechanism of generating secondary somatic drivers.

Functional activity related to being a super-enhancer or SNP site could underlie primary susceptibility to mutagenesis of a given locus, but it requires a repair process that generates large tandem duplications to confer selective advantage (Figure 5C). Tandem duplication mutagenesis is associated with DSB repair in the context of HR deficiency and is a potentially important mutagenic mechanism driving genetic diversity in evolving cancers by increasing copy number of portions of coding and non-coding genome. It could directly increase the number of copies of an oncogene or alter non-coding sites where super-enhancers/risk loci<sup>24</sup> are situated. It could therefore produce a spectrum of driver consequences<sup>25,26</sup>, ranging from strong effects in coding sequences to weaker effects in the coding and non-coding genome, profoundly, supporting a polygenic model of cancer development.

## **Conclusions**

Structural mutability in the genome is not uniform. It is influenced by forces of selection and by mutational mechanisms, with recombination-based repair playing a

critical role in specific genomic regions. Mutational processes may however not simply be passive contrivances. Some are possibly more harmful than others. We suggest that mutation signatures that confer a high degree of genome-wide variability are potentially more deleterious for somatic cells and thus more clinically relevant. Translational efforts should be focused on identifying and managing these adverse mutational processes in human cancer.

### **Author contributions**

D.G. and S.N-Z designed the study, analysed data and wrote the manuscript.

M.R.S., P.J.C., D.E, G.E., contributed towards idea development.

D.G. and S.M. performed all statistical analyses.

H.R.D., S.M., J.D.P., J.S., M.S. and X.Z. performed curation and contributed towards analyses.

M.S., contributed towards curation and analysis of transcriptomic data.

Y.L., L.B.A. contributed towards analysis.

C.P., P.T.S., S.R.L., I.H.R., H.R., contributed pathology assessment and/or samples and FISH analyses.

K.R. contributed IT expertise.

All authors discussed the results and commented on the manuscript.

### **Acknowledgements**

Data used in this analysis was funded through the ICGC Breast Cancer Working group by the Breast Cancer Somatic Genetics Study (BASIS), a European research project funded by the European Community's Seventh Framework Programme (FP7/2010-2014) under the grant agreement number 242006; the Triple Negative project funded by the Wellcome Trust (grant reference 077012/Z/05/Z) and the HER2+ project funded by Institut National du Cancer (INCa) in France (Grants N° 226-2009, 02-2011, 41-2012, 144-2008, 06-2012). The ICGC Asian Breast Cancer Project was funded through a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111218-SC01).

Funding: This work is funded by a Wellcome Trust Strategic Award (101126/B/13/Z). DG is supported by the EU-FP7-SUPPRESSTEM project. SN-Z is funded by a Wellcome Trust Intermediate Fellowship (WT100183MA) and is a Wellcome Beit Fellow.

### **Conflicts of interest**

The authors have no conflicts of interest to declare.

### **References**

1. Nik-Zainal, S. A compendium of 560 breast cancer genomes. *Nature* (2016).
2. Huang, F.W. *et al.* Highly recurrent TERT promoter mutations in human melanoma. *Science* **339**, 957-9 (2013).
3. Vinagre, J. *et al.* Frequency of TERT promoter mutations in human cancers. *Nat Commun* **4**, 2185 (2013).
4. Puente, X.S. *et al.* Non-coding recurrent mutations in chronic lymphocytic leukaemia. *Nature* **526**, 519-24 (2015).
5. Alexandrov, L.B. *et al.* Signatures of mutational processes in human cancer. *Nature* **500**, 415-21 (2013).
6. Mehta, A. & Haber, J.E. Sources of DNA double-strand breaks and models of recombinational DNA repair. *Cold Spring Harb Perspect Biol* **6**, a016428 (2014).
7. Ceccaldi, R., Rondinelli, B. & D'Andrea, A.D. Repair Pathway Choices and Consequences at the Double-Strand Break. *Trends Cell Biol* **26**, 52-64 (2016).
8. al, M.e. The topography of mutational processes in 560 breast cancer genomes. *Nature Communications* (2016).

9. Helleday, T., Eshtad, S. & Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. *Nat Rev Genet* **15**, 585-98 (2014).
10. Nik-Zainal, S. *et al.* Mutational processes molding the genomes of 21 breast cancers. *Cell* **149**, 979-93 (2012).
11. Nilsson, B., Johansson, M., Heyden, A., Nelander, S. & Fioretos, T. An improved method for detecting and delineating genomic regions with altered gene expression in cancer. *Genome Biol* **9**, R13 (2008).
12. Nilsen, G. *et al.* Copynumber: Efficient algorithms for single- and multi-track copy number segmentation. *BMC Genomics* **13**, 591 (2012).
13. Menghi, F. *et al.* The tandem duplicator phenotype as a distinct genomic configuration in cancer. *Proc Natl Acad Sci U S A* **113**, E2373-82 (2016).
14. Garcia-Closas, M. *et al.* Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nat Genet* **45**, 392-8, 398e1-2 (2013).
15. Easton, D.F. *et al.* Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* **447**, 1087-93 (2007).
16. Li, S. *et al.* Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. *Cell Rep* **4**, 1116-30 (2013).
17. Robinson, D.R. *et al.* Activating ESR1 mutations in hormone-resistant metastatic breast cancer. *Nat Genet* **45**, 1446-51 (2013).
18. Soucek, L. *et al.* Modelling Myc inhibition as a cancer therapy. *Nature* **455**, 679-83 (2008).
19. Shi, J. *et al.* Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. *Genes Dev* **27**, 2648-62 (2013).
20. Zhang, X. *et al.* Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. *Nat Genet* **48**, 176-82 (2016).
21. Costantino, L. *et al.* Break-induced replication repair of damaged forks induces genomic duplications in human cells. *Science* **343**, 88-91 (2014).
22. Willis, N.A., Rass, E. & Scully, R. Deciphering the Code of the Cancer Genome: Mechanisms of Chromosome Rearrangement. *Trends Cancer* **1**, 217-230 (2015).
23. Saini, N. *et al.* Migrating bubble during break-induced replication drives conservative DNA synthesis. *Nature* **502**, 389-92 (2013).
24. Sloan, C.A. *et al.* ENCODE data at the ENCODE portal. *Nucleic Acids Res* **44**, D726-32 (2016).
25. Castro-Giner, F., Ratcliffe, P. & Tomlinson, I. The mini-driver model of polygenic cancer evolution. *Nat Rev Cancer* **15**, 680-5 (2015).
26. Roy, A. *et al.* Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. *Nat Commun* **6**, 8891 (2015).

## Figure legends

**Figure 1: Spectrum of distribution of rearrangements in human breast cancers.**

**Circos plots depicting somatic rearrangements with chromosomal ideogram on**



**the outermost right and** lines representing rearrangements (green= tandem duplications, pink=deletions, blue=inversions and purple=interchromosomal events). **A**, quiescent tumor, **B**, tumor with focal “clustered” rearrangements, **C**, tumor with mainly tandem duplications distributed throughout the genome (“dispersed” rearrangements) **D**, tumor with a mixed pattern of dispersed rearrangements and clustered rearrangements. **E**, Rearrangement Signatures 1 and 3 comprise mainly tandem duplications but are characterised predominantly by tandem duplications of different lengths (>100kb and <10kb respectively).

**Figure 2: Identifying hotspots of rearrangements.** **A**, A schematic of dispersed rearrangements in the genomes of 5 hypothetical patients, with regions that are identified as hotspots by the PCF algorithm highlighted in beige. Note the differing sizes of each putative hotspot permitted through this method that negates the use of bins. **B**, Workflow of PCF application to rearrangement signatures. **C**, Rainfall plots of chromosome 8 rearrangements for tandem duplication signatures RS1 (>100kb) top panel and RS3 (<10kb) bottom panel. Inter-rearrangement distance is plotted on a log-scale on the y-axis. Black lines demonstrate PCF-defined hotspots. RS1 is 20 times more likely to form hotspots than RS3 and these are visible as punctuated collections of breakpoints in these plots.

**Figure 3: Hotspots of dispersed rearrangements: A large (>100kb) tandem duplication mutational process shows distinctive genomic overlap between patients and coincides with germline susceptibility loci and super-enhancer regulatory elements**

**A**, A summary of 33 hotspots of long tandem duplications (RS1) and, **B**, 4 hotspots of short tandem duplications (RS3). Higher panel shows density of rearrangement breakpoints within hotspots. The black horizontal lines denote the expected breakpoint density according to the background model. Lower panel shows frequency of each hotspot in the cohort of 560 patients. Hotspots that contain breast cancer susceptibility SNPs are marked with blue circles, and breast-specific super-enhancers marked with red triangles. Genes that may be relevant are highlighted although their true significance is uncertain. **C**, Two different hotspots of RS1: left panel (chr12:11.8Mb-12.8Mb) coincides with two breast tissue specific super-enhancers and right panel (chr8:116.6Mb-117.7Mb) coincides with a germline susceptibility locus of breast cancer. Nearby cancer genes are annotated, although relevance of these genes is uncertain. Next six panels depict genomic rearrangements for six individual patients at each locus. Copy number (y-axis) depicted as black dots (10kb bins). Green lines present tandem duplication breakpoints. Note the precise genomic overlap between patients. Lowermost panel presents cumulative number of samples with a rearrangement involving this genomic region, emphasizing at its peak, the region of critical genomic overlap between samples. Thick red lines represent breast-tissue specific super enhancers. Blue vertical line represents position of germline susceptibility locus of breast cancer. Relevant SNP rsID is provided.

**Figure 4: Genomic consequences of the tandem duplication signatures**

Tandem duplications can transect or duplicate genomic features like regulatory elements or genes. **A**, tandem duplications attributed to rearrangement signature RS1 often duplicate genomic regions containing breast cancer predisposition SNPs, breast tissue super-enhancers and oncogenes. RS1 rearrangements in hotspots show a

particular enrichment when compared to RS1 rearrangements that occur in other regions and when compared to simulated rearrangements. There are 524 RS1 duplications in hotspots, and 4,916 duplications outside of hotspots. **B**, tandem duplications attributed to RS3 in hotspots are enriched for transecting cancer genes more than in the rest of genome, or in simulated data. There are 57 RS3 duplications in hotspots, and 10,967 RS3 duplications outside of hotspots. Asterisks highlight statistically significant enrichment of any particular genomic feature within hotspots compared to outside hotspots, as calculated by two-sided Fisher's exact test. Four asterisks \*\*\*\* denote  $p$ -value  $P \leq 0.0001$ , \*\*  $P \leq 0.01$ , \*  $P \leq 0.05$ . Error bars show the standard deviation across ten different simulated datasets.

**Figure 5: From selective susceptibility to selective pressure?**

**A**, The spectrum of genomic structural variation at a single locus: *c-MYC*. Copy number (y-axis) depicted as black dots (10kb bins). Lines represent rearrangement breakpoints (green= tandem duplications, pink=deletions, blue=inversions and purple=interchromosomal events). Genes other than *c-MYC* were marked as black lines at the top of the panel. **B**, Cumulative number of samples with dispersed rearrangements within the *c-MYC*-related tandem duplication hotspot. A peak is observed very close to *c-MYC* but also flanking *c-MYC* where two germline susceptibility loci are observed. A large super-enhancer is also situated upstream of *c-MYC*. **C**, Putative model of cascade of events underlying the RS1-enriched hotspots in breast cancer. Sites enriched for super-enhancers (SENH) may be more highly transcribed and thus exposed to damage including DSB damage. Long tandem duplications are particularly at risk of copying whole genes in contrast to other rearrangement classes. Thus although other rearrangement classes may be found (in

low numbers in the same region), an enrichment of long tandem duplications is observed because of a small degree of selection in action.